Journal Watch · Journal of Allergy and Clinical Immunology · 2026

Clinical relevance of mosaic variants detected by exome sequencing.

Finally, chemotherapy drug resistance variants in NRAS, KRAS, and IDH2 were identified, demonstrating the potential for mosaic variant detection to inform treatment strategies.<h4>Conclusion</h4>Mosaic variants contribute significantly to the molecular diagnosis and prognosis of immune and hematologic disorders and are missed by typical germline variant-calling workflow.

Ghosh R, Fazal Z, Oler AJ et al.Journal of Allergy and Clinical Immunology3 min readPharma relevance 50/100

DOI: 10.1016/j.jaci.2026.02.011PMID: 41724404Study type: cohort / observational clinical study

TL;DR

Finally, chemotherapy drug resistance variants in NRAS, KRAS, and IDH2 were identified, demonstrating the potential for mosaic variant detection to inform treatment strategies.<h4>Conclusion</h4>Mosaic variants contribute significantly to the molecular diagnosis and prognosis of immune and hematologic disorders and are missed by typical germline variant-calling workflow.

Key findings

  • Clinically relevant parental mosaicism was ascertained in two families.
  • Enrichment of mosaic variants was observed in clonal hematopoiesis-related genes driven by older age and GATA2 deficiency, with prognostic implications for hematologic disorders.
  • Finally, chemotherapy drug resistance variants in NRAS, KRAS, and IDH2 were identified, demonstrating the potential for mosaic variant detection to inform treatment strategies.<h4>Conclusion</h4>Mosaic variants contribute significantly to the molecular diagnosis and prognosis of immune and hematologic disorders and are missed by typical germline variant-calling workflow.

Numbers at a glance (from the abstract)

1.4%31%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

A subset of the detected variants was orthogonally validated. Clinical data were retrospectively analyzed to assess the clinical significance of these variants.<h4>Results</h4>Mosaic variants associated with immune disorders contributed to a molecular diagnosis in 29 (1.4%) of 2064 affected participants. Notably, 9 (31%) of 29 of diagnostic variants were missed by standard germline analysis as a result of low variant allele fractions.

Full abstract (original)

Background: <h4>Background</h4>Mosaic variants represent a significant but underrecognized contributor to human disease such as cancer and immune diseases. Despite advances in genetic diagnostics, mosaic variant detection remains challenging as a result of low variant allele fractions, tissue specificity, and clinical heterogeneity.<h4>Objective</h4>We investigated the prevalence, diagnostic impact, and clinical relevance of mosaic variants in participants with immune disorders.<h4>Methods</h4>Exome sequencing of blood and/or saliva was performed in 2655 participants, including 2064 affected participants. Mosaic variants were detected using two algorithms, LoFreq2 and Mutect2.

What they did: A subset of the detected variants was orthogonally validated. Clinical data were retrospectively analyzed to assess the clinical significance of these variants.<h4>Results</h4>Mosaic variants associated with immune disorders contributed to a molecular diagnosis in 29 (1.4%) of 2064 affected participants. Notably, 9 (31%) of 29 of diagnostic variants were missed by standard germline analysis as a result of low variant allele fractions.

Results & conclusions: Clinically relevant parental mosaicism was ascertained in two families. Enrichment of mosaic variants was observed in clonal hematopoiesis-related genes driven by older age and GATA2 deficiency, with prognostic implications for hematologic disorders. Finally, chemotherapy drug resistance variants in NRAS, KRAS, and IDH2 were identified, demonstrating the potential for mosaic variant detection to inform treatment strategies.<h4>Conclusion</h4>Mosaic variants contribute significantly to the molecular diagnosis and prognosis of immune and hematologic disorders and are missed by typical germline variant-calling workflow.

Abstract © the authors / Journal of Allergy and Clinical Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.jaci.2026.02.011 · PubMed 41724404.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Journal of Allergy and Clinical Immunology study find?

Finally, chemotherapy drug resistance variants in NRAS, KRAS, and IDH2 were identified, demonstrating the potential for mosaic variant detection to inform treatment strategies.<h4>Conclusion</h4>Mosaic variants contribute significantly to the molecular diagnosis and prognosis of immune and hematologic disorders and are missed by typical germline variant-calling workflow.

What type of study is this?

It is a cohort / observational clinical study, published in Journal of Allergy and Clinical Immunology in 2026. A subset of the detected variants was orthogonally validated.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.jaci.2026.02.011. PubMed ID: 41724404. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Ghosh R, Fazal Z, Oler AJ et al.. Clinical relevance of mosaic variants detected by exome sequencing.. Journal of Allergy and Clinical Immunology (2026). DOI: 10.1016/j.jaci.2026.02.011.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/clinical-relevance-of-mosaic-variants-detected-by-exome-sequencing-602011/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides